TNFRSF10A anticorps (AA 2-203)

N° du produit ABIN5027281

Détail du produit anti-TNFRSF10A anticorps

Antigène: TNFRSF10A (Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A))

Épitope: AA 2-203

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF10A est non-conjugé

Application: Western Blotting (WB)

Purification: Protein G Chromatography

Immunogène: A partial length recombinant human TRAIL/DR4 protein (amino acids 2-203) was used as an immunogen for this antibody.

Clone: ABM1B11

Isotype: IgG1 kappa

Information d'application

Indications d'application: WB: 2-4 μg/mL

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: PBS containing 0.05 % BSA, PH 7.4

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Détails sur TNFRSF10A

Antigène: TNFRSF10A (Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A))

Autre désignation: TRAIL/DR4 (TNFRSF10A Produits)

Synonymes: anticorps APO2, anticorps CD261, anticorps DR4, anticorps TRAILR-1, anticorps TRAILR1, anticorps TNFRSF10A, anticorps TNF receptor superfamily member 10a, anticorps tumor necrosis factor receptor superfamily member 26, anticorps tumor necrosis factor receptor superfamily, member 10a, anticorps TNFRSF10A, anticorps LOC510798

Sujet: Death receptor 4 (DR4) or TRAIL-R1, a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. DR4 expression is enhanced by DNA damage whether induced by ionizing radiation or by chemotherapeutic agents. On binding DR4, TRAIL induces cell death via caspase-dependent apoptosis. DR4 mediate oligomeric Abeta induction of extrinsic apoptotic pathways in human microvascular cerebral endothelial cells with activation of both caspase-8 and caspase-9. It is considered a promising molecular target for cancer therapy.

Poids moléculaire: 50 kDa

ID gène: 8797

UniProt: O00220

Pathways: Apoptose, Positive Regulation of Endopeptidase Activity